The public , including those in elected office, seem to assume that the expected prohibition on sales and use by underage persons will somehow be enough to limit the damage.
The field is getting accustomed to patients arriving in addiction treatment complaining of problems with prescription opioids, stimulants, sedatives, etc, while actively enrolled in medical cannabis programs.
More likely the hope is to increase awareness of the risks, and encourage drinkers to limit consumption.
The goal is to eventually develop an objective scale by which pain can be measured not by self-report, but by neuroimaging.
So if some enterprising MD or PhD were to show with a proposal for research designed to prove that drinking has definite health benefits, the industry will throw money at it.
A new study may be exciting to read, but its credibility will ultimately depend on the accumulation of a body of evidence that confirms it.
After all, you can’t afford to stop selling it. That’s not how you get promoted. What you need is science that seems to confirm your biases.
A number of experts pointed out the risks associated with a dramatic increase in opioid prescribing. They were ignored in favor of others who downplayed those risks.